Back to News
Nov 18, 2025 12:00 PM

This Medical Device Maker Is Seeing High Demand In Cardiovascular, Diabetes Business

Medtronic Plc (NYSE:MDT) on Tuesday reported strong second-quarter 2026 results, with sales hitting $8.96 billion, surpassing the consensus estimate of $8.87 billion. This marks a 6.6% increase year-over-year, with organic growth of 5.5%.

Adjusted earnings of $1.36 per share also beat expectations of $1.31.

Cardiovascular Portfolio revenue reached $3.436 billion, up 10.8% (+9.3% organic), with a mid-teens increase in Cardiac Rhythm & Heart Failure, a high-single digit increase in Structural Heart & Aortic, and a low-single digit increase in Coronary & Peripheral Vascular.

Also Read: Analyst Sees Strong Medtronic Momentum Through 2026 With Buy Rating Intact

Neuroscience revenue increased 4.5% (+3.9%) to $2.562 ...